Literature DB >> 32169990

Rapidly progressive course of pauci-immune pulmonary capillaritis in a 70-year-old Asian male refractory to immunosuppression and plasma exchange.

Chuan Jiang1, Grace Nabila Martinez Pena2, Meng Xie3, Khalid Gafoor2.   

Abstract

A 70-year-old man presented with acute respiratory failure, alveolar infiltrates and haemoptysis requiring supplemental oxygen. Flexible bronchoscopy with bronchoalveolar lavage identifies diffuse alveolar haemorrhage. Clinical and serological evaluations do not identify a precise aetiology and histopathology establishes the diagnosis of isolated pauci-immune pulmonary capillaritis. The patient received induction therapy with high dose methylprednisolone at 1000 mg/day for 5 days and weekly rituximab at 375 mg/m2 scheduled over 4 weeks. Although the patient demonstrated clinical improvement after the first week, he experienced a rapid relapse requiring mechanical ventilation. His induction rituximab regimen was continued and plasma exchange was initiated. Despite these therapies, the patient's condition deteriorated and passed away. Our case adds insight to the management of this rare entity and describes the use of plasma exchange as salvage therapy. © BMJ Publishing Group Limited 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  connective tissue disease; intensive care; respiratory medicine; respiratory system; vasculitis

Mesh:

Substances:

Year:  2020        PMID: 32169990      PMCID: PMC7069264          DOI: 10.1136/bcr-2019-233577

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  33 in total

1.  Idiopathic pulmonary hemosiderosis: a rare cause of iron-deficiency anemia in childhood.

Authors:  Vincenzo Poggi; Andrea Lo Vecchio; Francesco Menna; Giuseppe Menna
Journal:  J Pediatr Hematol Oncol       Date:  2011-05       Impact factor: 1.289

2.  Rituximab versus cyclophosphamide for ANCA-associated vasculitis.

Authors:  John H Stone; Peter A Merkel; Robert Spiera; Philip Seo; Carol A Langford; Gary S Hoffman; Cees G M Kallenberg; E William St Clair; Anthony Turkiewicz; Nadia K Tchao; Lisa Webber; Linna Ding; Lourdes P Sejismundo; Kathleen Mieras; David Weitzenkamp; David Ikle; Vicki Seyfert-Margolis; Mark Mueller; Paul Brunetta; Nancy B Allen; Fernando C Fervenza; Duvuru Geetha; Karina A Keogh; Eugene Y Kissin; Paul A Monach; Tobias Peikert; Coen Stegeman; Steven R Ytterberg; Ulrich Specks
Journal:  N Engl J Med       Date:  2010-07-15       Impact factor: 91.245

3.  Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.

Authors:  Rachel B Jones; Jan Willem Cohen Tervaert; Thomas Hauser; Raashid Luqmani; Matthew D Morgan; Chen Au Peh; Caroline O Savage; Mårten Segelmark; Vladimir Tesar; Pieter van Paassen; Dorothy Walsh; Michael Walsh; Kerstin Westman; David R W Jayne
Journal:  N Engl J Med       Date:  2010-07-15       Impact factor: 91.245

Review 4.  Pulmonary vasculitis.

Authors:  Kevin K Brown
Journal:  Proc Am Thorac Soc       Date:  2006

5.  Diagnostic predictive value of ANCA serology.

Authors:  J C Jennette; A S Wilkman; R J Falk
Journal:  Kidney Int       Date:  1998-03       Impact factor: 10.612

6.  Alveolar hemorrhage in vasculitis: primary and secondary.

Authors:  Jean-François Cordier; Vincent Cottin
Journal:  Semin Respir Crit Care Med       Date:  2011-06-14       Impact factor: 3.119

Review 7.  Plasma exchange in the treatment of Wegener's granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome and renal limited vasculitis.

Authors:  Alina Casian; David Jayne
Journal:  Curr Opin Rheumatol       Date:  2011-01       Impact factor: 5.006

8.  The role of antineutrophil cytoplasmic antibody (c-ANCA) testing in the diagnosis of Wegener granulomatosis. A literature review and meta-analysis.

Authors:  J K Rao; M Weinberger; E Z Oddone; N B Allen; P Landsman; J R Feussner
Journal:  Ann Intern Med       Date:  1995-12-15       Impact factor: 25.391

9.  Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR Project for ANCA Assay Standardization.

Authors:  E C Hagen; M R Daha; J Hermans; K Andrassy; E Csernok; G Gaskin; P Lesavre; J Lüdemann; N Rasmussen; R A Sinico; A Wiik; F J van der Woude
Journal:  Kidney Int       Date:  1998-03       Impact factor: 10.612

10.  Treatment of life-threatening primary pulmonary hemosiderosis with cyclophosphamide.

Authors:  J L Colombo; S M Stolz
Journal:  Chest       Date:  1992-09       Impact factor: 9.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.